1. Home
  2. SVM vs MESO Comparison

SVM vs MESO Comparison

Compare SVM & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silvercorp Metals Inc.

SVM

Silvercorp Metals Inc.

N/A

Current Price

$12.65

Market Cap

2.1B

ML Signal

N/A

Logo Mesoblast Limited

MESO

Mesoblast Limited

N/A

Current Price

$16.64

Market Cap

2.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SVM
MESO
Founded
N/A
2004
Country
Canada
Australia
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.1B
IPO Year
2005
2005

Fundamental Metrics

Financial Performance
Metric
SVM
MESO
Price
$12.65
$16.64
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$10.50
N/A
AVG Volume (30 Days)
2.5M
176.8K
Earning Date
05-25-2026
02-26-2026
Dividend Yield
0.22%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$36.87
$629.74
Revenue Next Year
$35.34
$30.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.50
$12.66
52 Week High
$15.77
$21.50

Technical Indicators

Market Signals
Indicator
SVM
MESO
Relative Strength Index (RSI) 64.62 54.75
Support Level $11.45 $15.37
Resistance Level $13.22 $17.10
Average True Range (ATR) 0.56 0.37
MACD 0.13 0.09
Stochastic Oscillator 82.64 57.79

Price Performance

Historical Comparison
SVM
MESO

About SVM Silvercorp Metals Inc.

Silvercorp Metals Inc is engaged in the acquisition, exploration, development, and mining of mineral properties. The Company's producing mines are located in China, and current exploration and development projects are located in China, Ecuador and Kyrgyz Republic. The company operates in single segment. The Company mainly produces and sells silver, lead, zinc, gold and other metals. The company's producing projects are Ying Mining District, GC Mine; construction projects are El Domo; permitting project is BYP Mine; development project includes Condor, Tulkubash/Kyzyltash.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: